FDA approves long-acting injectable schizophrenia treatment

“This is the kind of news that makes you want to stand up and dance when you read it. I am eager to learn more about the details of Aristada. Imagine the future mental health management with injectable long-lasting psychosis medications.” Bill Chesnut, MD

 FDA approves long-acting injectable schizophrenia treatment

 The Wall Street Journal (10/6, Armental, Subscription Publication) reports that the Food and Drug Administration approved Aristada (aripiprazole lauroxil), Alkermes PLC’s drug to treat schizophrenia.

Bloomberg News (10/6, Chen) reports that Aristada is “a long-acting injectable medicine with options to be taken once monthly or every six weeks,” and is “intended as an alternative to oral anti-psychotic medications taken daily.”

AMA newsletter October, 2015.